

Ref: FOI/GS/ID 7652

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

08 September 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Treatments for Lung Cancer.

You asked:

Q1. In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:

- a. Afatinib*
- b. Alectinib*
- c. Atezolizumab monotherapy*
- d. Atezolizumab in combination*
- e. Bevacizumab*
- f. Brigatinib*
- g. Capmatenib*
- h. Ceritinib*
- i. Crizotinib*
- j. Dacomitinib*
- k. Dabrafenib with Trametinib*
- l. Docetaxel monotherapy*
- m. Durvalumab*
- n. Erlotinib*
- o. Gefitinib*
- p. Gemcitabine*
- q. Nintedanib with Docetaxel*
- r. Nivolumab*
- s. Osimertinib*
- t. Paclitaxel*
- u. Pembrolizumab monotherapy*
- v. Pembrolizumab in combination*
- w. Pemetrexed with Carboplatin/Cisplatin*

- x. *Tepotinib*
- y. *Vinorelbine with Cisplatin/Carboplatin*
- z. *Any other SACT*
- aa. *Palliative care only*

Trust response:

Q1.

- a. 2
- b. 6
- c. 0
- d. 0
- e. 0
- f. 0
- g. 0
- h. 0
- i. 1
- j. 0
- k. 1
- l. 2
- m. 1
- n. 0
- o. 0
- p. 0
- q. 2
- r. 0
- s. 11
- t. 0
- u. 14
- v. 11
- w. 1
- x. 0
- y. 1
- z. 5
- aa. 14